IL17A and psoriasis: Over the past few years, several studies have reported that targeted therapies against psoriasis cause eczematous damage, specifically the anti-tumor necrosis factor alpha (TNF-α) and anti-interleukin 17 (IL-17) therapies with ustekinumab, secukinumab, ixekizumab, etc. targeted therapeutic agents (14, 15).